广东方盛融华药业

Guangdong Fangsheng Ronghua Pharmaceutical is a subsidiary of Hunan Fangsheng Pharmaceutical, established in 2022 and based in Guangzhou, China. The company operates primarily as a Marketing Authorization Holder (MAH) and focuses on the research, development, and commercialization of innovative traditional Chinese medicines (TCM) and chemical drugs. Its key pipeline includes Relugolix tablets, for which it holds the MAH license, and innovative TCM candidates like gynecological hemostatic and analgesic granules, which are in Phase II/III clinical trials. Fangsheng Ronghua leverages a "research + industrialization" model to integrate R&D resources and expand its product portfolio in therapeutic areas such as gynecology and oncology.